Related Experiment Video
Updated: May 28, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways
Ileana-Raluca Pătru1,2, Dimitrie-Ionuț Atasiei1,3, Radu Tudor Ionescu4
1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Abstract:
Since the first approval of CTLA-4 blockade for melanoma, immune checkpoint inhibitors (ICIs) have expanded into a major class of cancer therapy, with more than 100 FDA-approved oncological indications across metastatic and earlier-stage disease settings, including use as monotherapy and in combination regimens. Preclinical research has largely focused on myocarditis and atherosclerosis, but a wider set of phenotypes, such as non-inflammatory left ventricular dysfunction (NILVD), arrhythmias, and vasculitis, can be observed, and they are rarely connected within a single mechanistic model. We aim to build a systems-oriented, mechanistic framework of the most widely studied biological processes; it will link the main checkpoint pathways to relevant cardiac and vascular cell types, molecular pathways, immune synapses, and candidate biomarkers. We searched PubMed, Scopus, and Web of Science using combinations of terms for immune checkpoint inhibition and cardiovascular-immune-related adverse events that provide mechanistic insight into cardiac-immune-related adverse reactions (irAEs). An AI-assisted semantic clustering approach was used only to organize the included literature. The integrated framework identifies PD-1/PD-L1 as the dominant mechanistic hub linking T-cell activation, endothelial recruitment, myocardial injury, and vascular inflammation. Across phenotypes, a shared immune core involving checkpoint pathways, cytokine signaling, and leukocyte trafficking coexists with phenotype-restricted mediators that may bias injury toward myocarditis, vascular inflammation, conduction-system disease, or NILVD. KEGG analyses support the enrichment of T-cell receptor signaling, Th17 differentiation, JAK-STAT signaling, cytokine-cytokine receptor interaction, and lipid and atherosclerosis pathways. Candidate biomarkers emerging from the reviewed literature include troponin, IL-6, CXCL9/CXCL10/CXCL13, S100A family proteins, ROCK2, HLA-linked susceptibility signals, and T-cell receptor clonality markers. The AI-assisted clustering broadly recapitulated the expert-defined thematic structure while identifying finer semantic neighborhoods within the literature. This framework provides a support map for further hypotheses about toxicity patterns with current and next-generation checkpoint strategies on the cardiac system, while AI-assisted clustering provides a complementary method for organizing the literature rather than an independent source of biological inference.
Insights
Immune checkpoint inhibitors (ICIs) can cause various cardiac issues. This study integrates pathways to explain cardiovascular toxicities, identifying PD-1/PD-L1 as a key hub and suggesting biomarkers for early detection.
Area of Science:
- Cardiovascular research
- Immunology
- Oncology
- Systems biology
Background:
- Immune checkpoint inhibitors (ICIs) are a major cancer therapy class with over 100 FDA-approved indications.
- While preclinical research focused on myocarditis and atherosclerosis, broader cardiovascular toxicities like non-inflammatory left ventricular dysfunction (NILVD), arrhythmias, and vasculitis occur.
- Existing models rarely connect these diverse cardiovascular immune-related adverse events (irAEs) mechanistically.
Purpose of the Study:
- To develop a systems-oriented framework linking immune checkpoint pathways to cardiovascular cell types, molecular pathways, and biomarkers.
- To elucidate the mechanistic basis of diverse cardiovascular irAEs associated with ICIs.
- To identify potential biomarkers for predicting and monitoring ICI-induced cardiac toxicity.
Main Methods:
- Systematic literature search of PubMed, Scopus, and Web of Science for ICI and cardiovascular irAE mechanisms.
- AI-assisted semantic clustering to organize and analyze the retrieved literature.
- Integration of findings into a mechanistic framework mapping checkpoint pathways to cardiac and vascular processes.
Main Results:
- The PD-1/PD-L1 pathway is identified as a central hub connecting T-cell activation, endothelial injury, myocardial damage, and vascular inflammation.
- A shared immune core (checkpoint pathways, cytokine signaling, leukocyte trafficking) underlies various irAE phenotypes, with specific mediators influencing injury type (myocarditis, NILVD, etc.).
- KEGG analyses revealed enrichment in T-cell receptor signaling, Th17 differentiation, JAK-STAT signaling, and lipid/atherosclerosis pathways.
- Candidate biomarkers include troponin, IL-6, CXCL9/10/13, S100 proteins, ROCK2, HLA-linked signals, and T-cell receptor clonality.
Conclusions:
- The developed framework provides a map for understanding ICI-related cardiac toxicities and generating new hypotheses.
- PD-1/PD-L1 blockade plays a critical role in mediating cardiovascular irAEs through shared and phenotype-specific mechanisms.
- AI-assisted clustering offers a complementary approach for literature organization in complex biological research.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
